English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.17 |
| Open | 2.17 |
| 1-Year Change | -12.15% |
| Day's Range | 2.17 - 2.22 |
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.
BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).
Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.
